HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial

MT Newswires Live

Yesterday

HUTCHMED (China) (HKG:0013) announced positive high-level results from its SANOVO China phase ІІІ trial in treatment-naïve patients with non-small cell lung cancer, according to a Monday Hong Kong bourse filing.

ORPATHYS plus TAGRІSSO significantly improved progression-free survival versus TAGRІSSO alone in both high MET and intention-to-treat patient populations.

The combination also showed an encouraging clinical benefit in overall survival in both populations, which was a secondary endpoint of the trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/news/2663579022"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2663579022\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2663579022?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-31 13:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2663579022","market":"sg","top_or_hot":-1,"title":"HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (China) (HKG:0013) announced positive high-level results from its SANOVO China phase ІІІ trial in treatment-naïve patients with non-small cell lung cancer, according to a Monday Hong Kong bourse filing.</p><p>ORPATHYS plus TAGRІSSO significantly improved progression-free survival versus TAGRІSSO alone in both high MET and intention-to-treat patient populations.</p><p>The combination also showed an encouraging clinical benefit in overall survival in both populations, which was a secondary endpoint of the trial.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED Sees Positive High Level Results in Lung Cancer Drug Combo Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-31 13:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> HUTCHMED (China) (HKG:0013) announced positive high-level results from its SANOVO China phase ІІІ trial in treatment-naïve patients with non-small cell lung cancer, according to a Monday Hong Kong bourse filing.</p><p>ORPATHYS plus TAGRІSSO significantly improved progression-free survival versus TAGRІSSO alone in both high MET and intention-to-treat patient populations.</p><p>The combination also showed an encouraging clinical benefit in overall survival in both populations, which was a secondary endpoint of the trial.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1588","symbol_name":"回港中概股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2663579022","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2663579022","pubTimestamp":1788154752,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED   announced positive high-level results from its SANOVO China phase  trial in treatment-nave patients with non-small cell lung cancer, according to a Monday Hong Kong bourse filing.ORPATHYS plus TAGRSSO significantly improved progression-free survival versus TAGRSSO alone in both high MET and intention-to-treat patient populations.The combination also showed an encouraging clinical benefit in overall survival in both populations, which was a secondary endpoint of the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1588":"回港中概股","BK1191":"制药","BK1587":"次新股","00013":"和黄医药"},"translate_title":"和黄医药在肺癌药物组合试验中取得积极的高水平结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1.5},"content_text":"HUTCHMED (China) (HKG:0013) announced positive high-level results from its SANOVO China phase ІІІ trial in treatment-naïve patients with non-small cell lung cancer, according to a Monday Hong Kong bourse filing.ORPATHYS plus TAGRІSSO significantly improved progression-free survival versus TAGRІSSO alone in both high MET and intention-to-treat patient populations.The combination also showed an encouraging clinical benefit in overall survival in both populations, which was a secondary endpoint of the trial.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}